These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38768445)

  • 1. Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma.
    Indini A; Gueli R; Cerati M; Rijavec E; Parravicini M; Casagrande S; Rovelli C; Grossi PA; Grossi F
    Melanoma Res; 2024 Aug; 34(4):386-389. PubMed ID: 38768445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma.
    Kim H; Ha SY; Kim J; Kang M; Lee J
    Curr Oncol; 2020 Aug; 27(4):e436-e439. PubMed ID: 32905211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rare case of eosinophilic gastritis induced by nivolumab therapy for metastatic melanoma.
    Tsuji A; Hiramatsu K; Namikawa S; Yamamoto A; Midori Y; Murata Y; Tanaka T; Nosaka T; Naito T; Takahashi K; Ofuji K; Matsuda H; Ohtani M; Imamura Y; Iino S; Hasegawa M; Nakamoto Y
    Clin J Gastroenterol; 2022 Oct; 15(5):876-880. PubMed ID: 35978213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
    Lasocki A; Smith K
    J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
    Janssen JC; van Dijk B; de Joode K; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Jalving M; de Jonge MJA; Joosse A; Kapiteijn E; Kamphuis-Huismans AM; Naipal KAT; Piersma D; Rikhof B; Westgeest HM; Vreugdenhil G; Oomen-de Hoop E; Mulder EEAP; van der Veldt AAM
    BMC Cancer; 2024 May; 24(1):632. PubMed ID: 38783238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab.
    Maloney AK; Giobbie-Hurder A; Katukota N; Fogarasi MC; Ott PA; Hodi FS; Sussman TA; Silk AW; Haq R; Liu D; Insco M; Buchbinder EI
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39209453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
    J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
    Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
    Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
    Alnabulsi R; Hussain A; DeAngelis D
    Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
    McDonald MA; Sanghvi P; Bykowski J; Daniels GA
    BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.
    Shoushtari AN; Friedman CF; Navid-Azarbaijani P; Postow MA; Callahan MK; Momtaz P; Panageas KS; Wolchok JD; Chapman PB
    JAMA Oncol; 2018 Jan; 4(1):98-101. PubMed ID: 28817755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I; Malinzak M; Salama AKS
    J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual checkpoint inhibitor-associated eosinophilic enteritis.
    Yang J; Lagana SM; Saenger YM; Carvajal RD
    J Immunother Cancer; 2019 Nov; 7(1):310. PubMed ID: 31730503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis.
    Bello E; Cohen JV; Mino-Kenudson M; Dougan M
    J Immunother Cancer; 2019 Feb; 7(1):41. PubMed ID: 30744698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
    Wolchok JD; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Butler MO; Hill A; Márquez-Rodas I; Haanen JBAG; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bas T; Ritchings C; Larkin J; Hodi FS
    J Clin Oncol; 2022 Jan; 40(2):127-137. PubMed ID: 34818112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.